<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Am J Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Am J Case Rep</journal-id>
      <journal-id journal-id-type="publisher-id">amjcaserep</journal-id>
      <journal-title-group>
        <journal-title>The American Journal of Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1941-5923</issn>
      <publisher>
        <publisher-name>International Scientific Literature, Inc.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27554644</article-id>
      <article-id pub-id-type="pmc">4999016</article-id>
      <article-id pub-id-type="doi">10.12659/AJCR.895839</article-id>
      <article-id pub-id-type="publisher-id">895839</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Seifert</surname>
            <given-names>Leon Louis</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-amjcaserep-17-605">
            <sup>A</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn2-amjcaserep-17-605">
            <sup>B</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn3-amjcaserep-17-605">
            <sup>C</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-605">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-17-605">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-17-605">
            <sup>F</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-605">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heinzow</surname>
            <given-names>Hauke</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-amjcaserep-17-605">
            <sup>A</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-605">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-17-605">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-17-605">
            <sup>F</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-605">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kabar</surname>
            <given-names>Iyad</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn3-amjcaserep-17-605">
            <sup>C</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-605">
            <sup>D</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-605">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Christensen</surname>
            <given-names>Stefan</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn2-amjcaserep-17-605">
            <sup>B</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-605">
            <sup>D</sup>
          </xref>
          <xref ref-type="aff" rid="af2-amjcaserep-17-605">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>H&#xFC;sing</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn3-amjcaserep-17-605">
            <sup>C</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-605">
            <sup>D</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-605">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>Hartmut H.-J.</given-names>
          </name>
          <xref ref-type="corresp" rid="c1-amjcaserep-17-605"/>
          <xref ref-type="author-notes" rid="fn1-amjcaserep-17-605">
            <sup>A</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-605">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-17-605">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-17-605">
            <sup>F</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-605">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="af1-amjcaserep-17-605"><label>1</label>Department of Transplantation Medicine, University Hospital M&#xFC;nster, M&#xFC;nster, Germany</aff>
      <aff id="af2-amjcaserep-17-605"><label>2</label>Center for Interdisciplinary Medicine (CIM) Infectious Diseases, M&#xFC;nster, Germany</aff>
      <author-notes>
        <fn>
          <p>Authors&#x2019; Contribution:</p>
        </fn>
        <fn id="fn1-amjcaserep-17-605">
          <label>A</label>
          <p>Study Design</p>
        </fn>
        <fn id="fn2-amjcaserep-17-605">
          <label>B</label>
          <p>Data Collection</p>
        </fn>
        <fn id="fn3-amjcaserep-17-605">
          <label>C</label>
          <p>Statistical Analysis</p>
        </fn>
        <fn id="fn4-amjcaserep-17-605">
          <label>D</label>
          <p>Data Interpretation</p>
        </fn>
        <fn id="fn5-amjcaserep-17-605">
          <label>E</label>
          <p>Manuscript Preparation</p>
        </fn>
        <fn id="fn6-amjcaserep-17-605">
          <label>F</label>
          <p>Literature Search</p>
        </fn>
        <fn id="fn7-amjcaserep-17-605">
          <label>G</label>
          <p>Funds Collection</p>
        </fn>
        <fn>
          <p><bold>Conflict of interest:</bold> None declared</p>
        </fn>
        <corresp id="c1-amjcaserep-17-605">Corresponding Authors: Hartmut H.-J. Schmidt, e-mail: <email>hepar@ukmuenster.de</email>, Leon Louis Seifert, e-mail: <email>leon.seifert@uni-muenster.de</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <volume>17</volume>
      <fpage>605</fpage>
      <lpage>610</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>9</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Am J Case Rep, 2016</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license>
          <license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)</license-p>
        </license>
      </permissions>
      <abstract>
        <p>
          <bold>Patient: Male, 37</bold>
        </p>
        <p>
          <bold>Final Diagnosis: Chronic HCV-infection &#x2022; hepatic decompensation</bold>
        </p>
        <p>
          <bold>Symptoms: Esophageal varices &#x2022; portal-hypertensive gastropathy &#x2022; splenomegaly &#x2022; recurrent ascitic decompensation &#x2022; hepatorenal syndrome &#x2022; hepatic encephalopathy</bold>
        </p>
        <p>
          <bold>Medication: &#x2014;</bold>
        </p>
        <p>
          <bold>Clinical Procedure: Liver transplantation &#x2022; antiviral therapy</bold>
        </p>
        <p>
          <bold>Specialty: Gastroenterology and Hepatology</bold>
        </p>
        <sec>
          <title>Objective:</title>
          <p>
            <bold>Unusual setting of medical care</bold>
          </p>
        </sec>
        <sec>
          <title>Background:</title>
          <p>Direct-acting antivirals (DAAs) represent a new hallmark in antiviral therapy of hepatitis C virus (HCV). DAAs have been shown to be safe and effective after liver transplantation (LT), but there is little information about their use in peritransplant settings. Former intravenous drug users represent an increasing group seeking HCV treatment. This case report demonstrates the successful peritransplant antiviral treatment of a former intravenous drug user who had been treated in a methadone maintenance program.</p>
        </sec>
        <sec>
          <title>Case Report:</title>
          <p>The patient was diagnosed with Child B cirrhosis for the first time in 2009. He had a Model for End-stage Liver Disease (MELD) score of 21 and started antiviral therapy with sofosbuvir (SOF) and daclatasvir (DCV) in March 2014. Due to hepatic decompensation, he received a LT in April 2014. Immunosuppression was performed with tacrolimus (TAC) and mycophenolate-mofetil (MMF), and boosted with prednisolone in the initial stage. Four weeks after his LT, the patient presented with an acute renal injury. The patient was discharged one week later after sufficient hydration, discontinuation of non-steroidal anti-phlogistics therapy, and adjustments to his immunosuppressive regimen. At the beginning of his therapy, the number of RNA copies was 13,000 IU/mL. He received 24 weeks of anti-HCV treatment with SOF and DCV; the antiviral treatment was successful and his LT was well tolerated.</p>
        </sec>
        <sec>
          <title>Conclusions:</title>
          <p>Treatment of HCV is feasible in a peritransplant setting. The antiviral regimen we used did not seem to have any relevant interactions with the patient&#x2019;s immunosuppressive regimens. Still, the peritransplant setting is a very demanding environment for anti-HCV therapy, and further studies are needed.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>MeSH Keywords</title>
        <kwd>Antiviral Agents</kwd>
        <kwd>Drug Users</kwd>
        <kwd>Hepatitis C</kwd>
        <kwd>Liver Transplantation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Chronic hepatitis C (CHC) is major health problem; 80% of infected patients will develop CHC, leading to 180 million chronically infected patients worldwide [<xref rid="b1-amjcaserep-17-605" ref-type="bibr">1</xref>,<xref rid="b2-amjcaserep-17-605" ref-type="bibr">2</xref>].</p>
      <p>A chronic infection is highly correlated with an increased risk of hepatic inflammation and liver fibrosis, creating a significantly increased risk of developing liver cirrhosis and hepatocellular carcinoma [<xref rid="b3-amjcaserep-17-605" ref-type="bibr">3</xref>]. CHC is currently the most common reason for liver transplantation (LT) [<xref rid="b4-amjcaserep-17-605" ref-type="bibr">4</xref>&#x2013;<xref rid="b6-amjcaserep-17-605" ref-type="bibr">6</xref>]. At the same time, a recurrence of hepatitis C (HCV) after LT is common, and often results in a poor outcome. The rate of survival of the liver graft and the survival of the patient are reduced by hepatitis C infection [<xref rid="b4-amjcaserep-17-605" ref-type="bibr">4</xref>&#x2013;<xref rid="b9-amjcaserep-17-605" ref-type="bibr">9</xref>]. After having minimized the risk of HCV infection via blood transfusions in the 1990s, intravenous (IV) drug use is today the most common route of infection with HCV in many countries [<xref rid="b10-amjcaserep-17-605" ref-type="bibr">10</xref>,<xref rid="b11-amjcaserep-17-605" ref-type="bibr">11</xref>]. Former intravenous drug users and current methadone maintenance patients are consequently a growing group of patients seeking HCV treatment and LT.</p>
      <p>In the past, an interferon (IFN)-based antiviral therapy combined with the nucleoside analogue ribavirin (RBV) was the hallmark of treatment of CHC, but success rates remained unsatisfactory even after the introduction of the first generation of DAAs such as telaprevir and boceprevir [<xref rid="b12-amjcaserep-17-605" ref-type="bibr">12</xref>&#x2013;<xref rid="b26-amjcaserep-17-605" ref-type="bibr">26</xref>].</p>
      <p>Since the approval of second generation DAAs in 2014, antiviral therapy has become more feasible, with a broad arsenal of highly active DAAs available, including different drug groups with different antiviral mechanisms that affect HCV genes NS3/4A, NS5A, and NS5B [<xref rid="b27-amjcaserep-17-605" ref-type="bibr">27</xref>]. There have been several studies involving the new DAAs that show sustained virologic response (SVR) is achievable for a majority of patients, dependent on the underlying genotype and stage of the liver disease [<xref rid="b28-amjcaserep-17-605" ref-type="bibr">28</xref>&#x2013;<xref rid="b32-amjcaserep-17-605" ref-type="bibr">32</xref>]. In the context of HCV treatment after LT, the new treatment options represent a triumph for HCV research [<xref rid="b33-amjcaserep-17-605" ref-type="bibr">33</xref>&#x2013;<xref rid="b35-amjcaserep-17-605" ref-type="bibr">35</xref>].</p>
      <p>However, experiences with DAAs in a peritransplant setting are rare. The complexity of interactions in patients in this setting includes drug metabolism and the decompensated state of a patient that may be complicated by anti-HCV treatment. Thus the peritransplant setting is a very interesting area for research. The necessity of participation in a methadone maintenance program additionally complicates the demands of preitransplant treatment. In our case report, we present a case of a patient who was in a methadone maintenance program and was being treated with a combination of SOF and DCV peritransplant.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>The patient was first diagnosed with CHC (genotype 3a) in 1996. Past medical history revealed intravenous drug abuse. He participated in a methadone maintenance program starting in 2007. His last withdrawal therapy took place in late 2012. The first diagnosis of Child B cirrhosis was in 2009. The patient was subsequently in medical care because of esophageal varices with several ligation therapies, portal hypertensive gastropathy, splenomegaly, recurrent ascitic decompensation, hepatorenal syndrome, and hepatic encephalopathy. The patient presented himself in February 2014 in reduced general condition for evaluation for a LT with a Model for End-stage Liver Disease (MELD) score of 21. In the following weeks, a further worsening of the patient&#x2019;s condition was observed, leading to a MELD score of 28 in late March. Antiviral treatment was started with sofosbuvir (SOF) 400 mg/day and daclatasvir (DCV) 60 mg/day (as compassionate use) in March 2014, just 18 days before a liver graft was available for him. The antiviral therapy was administered for 24 weeks without dose adjustments. Our patient received a liver transplant in April 2014 at the age of 37 years with a MELD score of 33. Immunosuppression was started with a combination of tacrolimus (TAC), mycophenolate mofetil (MMF), and boosted with prednisolone in the initial stage. The liver transplantation was conducted using piggy-back technique with a graft from a 45-year-old, male donor. Cold ischemic time was nine hours, warm ischemic time was 40 minutes.</p>
      <p>The patient tolerated the transplantation well. Replacement therapy with L-polamidone had to be supplemented with dipyrone and clonidine during the patient&#x2019;s hospital stay. The patient received palladon retard twice daily and non-retard on demand. As was to be expected, the level of transaminases diminished postoperatively. From the second day, parameters of cholestasis increased as well as bilirubin, informing the decision to perform an endoscopic retrograde cholangiopancreatography (ERCP) on day four post-surgery. A sphincter of Oddi dysfunction was diagnosed. As the result of a papillotomy and the implantation of a stent in the ductus hepaticus communis (DHC), the parameters of cholestasis and bilirubin declined adequately.</p>
      <p>The renal function was limited preoperatively in terms of hepatorenal syndrome. Post-LT renal function was ameliorated with drinking volume restriction and the application of torsemide 10 mg twice daily. The patient was discharged from the hospital 17 days after his LT.</p>
      <p>One week after discharge, our patient was readmitted to the hospital because of an acute renal injury (classified as Acute Kidney Injury Network II &#x2013; AKIN II). His general state and renal function changed for the better after sufficient hydration and discontinuation of therapy with non-steroidal antiphlogistics (NSAPs). Furthermore, the dose of both immunosuppressive agents was reduced.</p>
      <p>In the course of the following months, our patient presented himself regularly to our hospital for control esophagogastroduodenoscopies (EGDs) and ERCPs. A stent exchange as well as treatment of a mucosal irritation with proton-pump inhibitors (PPIs) became necessary. The time course of TAC (FK506) levels and dosages of TAC and MMF are presented in <xref ref-type="fig" rid="f1-amjcaserep-17-605">Figure 1</xref>. Laboratory parameters for the first six weeks after LT are presented in <xref ref-type="table" rid="t1-amjcaserep-17-605">Table 1</xref>. Reactivation of CMV or EBV did not occur. Further, follow-up after LT was satisfactory, and no major complications occurred.</p>
      <p>The antiviral treatment was: SOF (400 mg/day) and DCV (60 mg/day) for 24 weeks until September 2014. Our patient started treatment with 13,000 IU/mL detectable RNA copies. The therapy was started 18 days prior to the transplantation. Five days post-LT, a small number of RNA copies (65 IU/mL) was detected. In the further course of treatment, HCV-RNA remained undetectable, yielding a SVR for our patient. The antiviral treatment provoked no severe adverse events in our patient, who had been treatment-naive previously.</p>
      <p>Our patient tolerated the combined liver transplantation and antiviral therapy very well, which is remarkable given his complicated circumstances. In the follow-up period, a liver biopsy showed no episode of transplant rejection reaction, and according to laboratory parameters and ultrasonography, the function of his liver graft has been normal. HCV-RNA has remained undetectable for more than 18 months.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>HCV infection is very common among intravenous drug users, as IV drug use is the major route of transmission of HCV in Western countries [<xref rid="b35-amjcaserep-17-605" ref-type="bibr">35</xref>&#x2013;<xref rid="b44-amjcaserep-17-605" ref-type="bibr">44</xref>]. Participation in a methadone maintenance program is the most effective and common mode of treatment for these patients [<xref rid="b45-amjcaserep-17-605" ref-type="bibr">45</xref>,<xref rid="b46-amjcaserep-17-605" ref-type="bibr">46</xref>]. Listing patients participating in a methadone maintenance program for liver transplantation is still a highly controversial topic. Thus, experience in the outcome of LT in this subset of patients is limited, but the results do not seem to differ from other LT patients [<xref rid="b47-amjcaserep-17-605" ref-type="bibr">47</xref>&#x2013;<xref rid="b50-amjcaserep-17-605" ref-type="bibr">50</xref>]. The accessibility of the new DAAs for former drug-users is another topic of contestation, due to the high cost of new regimens and required compliance of patients. Treatment and follow-up of a methadone patient in the context of concurrent antiviral therapy and a liver transplantation can be very demanding.</p>
      <p>Peritransplant setting, preexisting renal insufficiency, history of former IV drug abuse, and ongoing necessity of participation in a methadone maintenance program complicated the anti-HCV therapy in our patient. Whereas studies have proved the efficiency and safety of DAAs in patients who already have a LT, experiences with patients on antiviral therapy peritransplant are absent. A decreasing liver function requires dose adjustments for most drugs, and unlike other DAAs (simeprevir, paritaprevir, ombitasvir, dasabuvir) for which a contraindication exists in cases of cirrhosis more severe than Child A, SOF is safe even in case of Child C cirrhosis [<xref rid="b51-amjcaserep-17-605" ref-type="bibr">51</xref>]. In addition, DCV can also be administered in patients with hepatic failure. Due to its very low median effective dose, it is the most potent of the existing DAAs [<xref rid="b51-amjcaserep-17-605" ref-type="bibr">51</xref>]. Therefore, starting the antiviral therapy with SOF and DCV seemed feasible in our patient, even though the increasing MELD score indicated aggravating hepatic failure.</p>
      <p>Acute renal injury is common among liver transplant recipients, in particular, shortly after transplantation [<xref rid="b52-amjcaserep-17-605" ref-type="bibr">52</xref>]. In our patient, a renal insufficiency was already present prior to LT and recurred in the form of an acute renal injury after LT. The acute kidney injury (AKIN II) after LT additionally complicated our patient&#x2019;s therapy. In the presence of an estimated glomerular filtration rate (eGFR) &lt;30 mL/minute, which was observed in our patient at the beginning of the fourth week after LT, there is no existing dose recommendation for SOF [<xref rid="b51-amjcaserep-17-605" ref-type="bibr">51</xref>]. However, a dose reduction was assumed to be necessary for all DAAs. Studies suggest that for DCV, no dose reduction is necessary in cases of both hepatic and renal failure [<xref rid="b51-amjcaserep-17-605" ref-type="bibr">51</xref>,<xref rid="b53-amjcaserep-17-605" ref-type="bibr">53</xref>,<xref rid="b54-amjcaserep-17-605" ref-type="bibr">54</xref>]. For our patient renal function could be recovered, and hence there was no indication for a change in the dose of SOF.</p>
      <p>Kidney function affects immunosuppressive therapy, too. It is common among liver transplant recipients to administer an immunosuppressive regimen with a calcineurin inhibitor (TAC), and MMF as an inhibitor of inosine monophosphate through its active metabolite mycophenolic acid. Glucocorticoids are known to encourage a recurrence of HCV after LT and therefore are abandoned as possible therapy in immunosuppressive regimens for HCV patients [<xref rid="b55-amjcaserep-17-605" ref-type="bibr">55</xref>].</p>
      <p>In our patient&#x2019;s case, adaption of immunosuppressive medication was necessary, and, indeed, rescued the patient from renal failure in combination with sufficient hydration and discontinuation of NSAPs. Because TAC is known to have a possible harmful effect on renal function and the levels of TAC were too high in our patient&#x2019;s blood, the dose was reduced. In the presence of renal failure, the dosage of MMF also has to be reduced [<xref rid="b56-amjcaserep-17-605" ref-type="bibr">56</xref>]. In addition, an accumulation of TAC is known to occur in the presence of MMF and vice versa [<xref rid="b57-amjcaserep-17-605" ref-type="bibr">57</xref>,<xref rid="b58-amjcaserep-17-605" ref-type="bibr">58</xref>]. In our patient, the reduction of both dosages yielded a satisfactory level of TAC in the patient&#x2019;s blood and an improved condition of the patient.</p>
      <p>Despite the complicated peritransplant setting, including an increasing MELD score and an acute renal injury in a patient on methadone, the treatment with SOF and DCV was successful and required no dose adjustments. The results of recent studies on HCV therapy with DAAs represent an extraordinary opportunity for progress in the history of HCV infection and in the history of infectious diseases in general. Obviously, these advances will diminish the quantity of HCV-infected patients who will need a LT in the future. CHC may be replaced by other hepatological diseases as the most common reason for LT. Despite of all the triumphs in transplant-naive patients concerning the rate of SVR, the necessity of a liver transplantation may not be prevented but only postponed. The recommendation to prioritize fibrotic patients with a METAVIR (Meta-analysis of Histological Data in Viral Hepatitis) score of 3&#x2013;4 for treatment with DAAs is surely understandable considering the high healthcare system cost of these treatments [<xref rid="b59-amjcaserep-17-605" ref-type="bibr">59</xref>]. Nevertheless, a restriction of treatment to fibrotic patients may lead to reduced prevention of the necessity of a LT. An increasing frequency of peritransplant anti-HCV treatments is assumable. Consequently, the number of anti-HCV therapies in patients with a high MELD score and/or an acute kidney injury is also likely to grow. More experience in anti-HCV therapy in these complex patients is needed.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>Despite the aggravating circumstances in the peritransplant setting for our patient, anti-HCV therapy was successfully administered. In our patient&#x2019;s case, the necessity of a LT was foreseeable and viral clearance was desired before the LT to improve the patient and graft outcomes post-LT. A combination therapy with SOF (400 mg/day) and DCV (60 mg/day) seemed to be safe and effective in a peritransplant setting. Patients on methadone may need psychological therapy to ensure continuation of the treatment and to reduce the risk of reinfection via IV drug use. Further treatment experiences in this patient population are needed, as the number of peritransplant anti-HCV treatments will likely increase within the next few years.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References:</title>
      <ref id="b1-amjcaserep-17-605">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcellin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis C: The clinical spectrum of the disease</article-title>
          <source>J Hepatol</source>
          <year>1999</year>
          <volume>31</volume>
          <fpage>9</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">10622554</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-amjcaserep-17-605">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanafiah</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Groeger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Flaxman</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Wiersma</surname>
              <given-names>ST</given-names>
            </name>
          </person-group>
          <article-title>Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence</article-title>
          <source>Hepatology</source>
          <year>2013</year>
          <volume>57</volume>
          <fpage>1333</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">23172780</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-amjcaserep-17-605">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zoulim</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chevallier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maynard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trepo</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Clinical consequences of hepatitis C virus infection</article-title>
          <source>Rev Med Virol</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>57</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">12516062</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-amjcaserep-17-605">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis C, and liver transplantation</article-title>
          <source>Nature</source>
          <year>2005</year>
          <volume>436</volume>
          <fpage>973</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">16107838</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-amjcaserep-17-605">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crespo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Navasa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Forns</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Viral hepatitis in liver transplantation</article-title>
          <source>Gastroenterology</source>
          <year>2012</year>
          <volume>142</volume>
          <fpage>1373</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">22537446</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-amjcaserep-17-605">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joshi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pinzani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carey</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Recurrent HCV after liver transplantation- mechanisms, assessment and therapy</article-title>
          <source>Nat Rev Gastroenterol Hepatol</source>
          <year>2014</year>
          <volume>11</volume>
          <fpage>710</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">25023032</pub-id>
        </element-citation>
      </ref>
      <ref id="b7-amjcaserep-17-605">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berenguer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lopez-Labrador</surname>
              <given-names>FX</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis C and liver transplantation</article-title>
          <source>J Hepatol</source>
          <year>2001</year>
          <volume>35</volume>
          <fpage>666</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">11690716</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-amjcaserep-17-605">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Retortillo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Forns</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Feliu</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatitis C virus kinetics during and immediately after liver transplantation</article-title>
          <source>Hepatology</source>
          <year>2002</year>
          <volume>35</volume>
          <fpage>680</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">11870384</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-amjcaserep-17-605">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiesner</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Sorrell</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Villamil</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C</article-title>
          <source>Liver Transpl</source>
          <year>2003</year>
          <volume>9</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">12514766</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-amjcaserep-17-605">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Wasley</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Simard</surname>
              <given-names>EP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The prevalence of hepatitis C infection in the United States, 1999 through 2002</article-title>
          <source>Ann Intern Med</source>
          <year>2006</year>
          <volume>144</volume>
          <fpage>705</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">16702586</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-amjcaserep-17-605">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dienstag</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis C: A bitter harvest</article-title>
          <source>Ann Intern Med</source>
          <year>2006</year>
          <volume>144</volume>
          <fpage>770</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">16702593</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-amjcaserep-17-605">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manns</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>McHutchison</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>SC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial</article-title>
          <source>Lancet</source>
          <year>2001</year>
          <volume>358</volume>
          <fpage>958</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">11583749</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-amjcaserep-17-605">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fried</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Shiffman</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>KR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>347</volume>
          <fpage>975</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">12324553</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-amjcaserep-17-605">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beckebaum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cicinnati</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study</article-title>
          <source>Transplant Proc</source>
          <year>2004</year>
          <volume>36</volume>
          <fpage>1489</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">15251366</pub-id>
        </element-citation>
      </ref>
      <ref id="b15-amjcaserep-17-605">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chalasani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Manzarbeitia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferenci</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials</article-title>
          <source>Hepatology</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>289</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">15660392</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-amjcaserep-17-605">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biselli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Andreone</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gramenzi</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in na&#x131;ve and non-responder patients on a stable immunosuppressive regimen</article-title>
          <source>Dig Liver Dis</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>27</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">16311084</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-amjcaserep-17-605">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heydtmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Freshwater</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dudley</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation</article-title>
          <source>Am J Transplant</source>
          <year>2006</year>
          <volume>6</volume>
          <fpage>825</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">16539640</pub-id>
        </element-citation>
      </ref>
      <ref id="b18-amjcaserep-17-605">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neumann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Puhl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bahra</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin</article-title>
          <source>Transplantation</source>
          <year>2006</year>
          <volume>82</volume>
          <fpage>43</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="pmid">16861940</pub-id>
        </element-citation>
      </ref>
      <ref id="b19-amjcaserep-17-605">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fontana</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ciuffreda</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Moradpour</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation</article-title>
          <source>Transplantation</source>
          <year>2007</year>
          <volume>83</volume>
          <fpage>525</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">17318091</pub-id>
        </element-citation>
      </ref>
      <ref id="b20-amjcaserep-17-605">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roche</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sebagh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Canfora</surname>
              <given-names>ML</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis</article-title>
          <source>Liver Transpl</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>1766</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">19025933</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-amjcaserep-17-605">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dumortier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Scoazec</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Chevallier</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination</article-title>
          <source>J Hepatol</source>
          <year>2004</year>
          <volume>40</volume>
          <issue>4</issue>
          <fpage>669</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">15030984</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-amjcaserep-17-605">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akamatsu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sugawara</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Liver transplantation and hepatitis C</article-title>
          <source>Int J Hepatol</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>686135</fpage>
          <pub-id pub-id-type="pmid">22900194</pub-id>
        </element-citation>
      </ref>
      <ref id="b23-amjcaserep-17-605">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarrazin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cornberg</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C</article-title>
          <source>Z Gastroenterol</source>
          <year>2012</year>
          <volume>50</volume>
          <fpage>57</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">22222799</pub-id>
        </element-citation>
      </ref>
      <ref id="b24-amjcaserep-17-605">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Degasperi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Aghemo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives</article-title>
          <source>Hepat Med</source>
          <year>2014</year>
          <volume>6</volume>
          <fpage>25</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">24822024</pub-id>
        </element-citation>
      </ref>
      <ref id="b25-amjcaserep-17-605">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>H&#xE9;zode</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fontaine</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dorival</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
            <collab>CUPIC Study Group</collab>
          </person-group>
          <article-title>Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis</article-title>
          <source>Gastroenterol</source>
          <year>2014</year>
          <volume>147</volume>
          <fpage>132</fpage>
          <lpage>42</lpage>
        </element-citation>
      </ref>
      <ref id="b26-amjcaserep-17-605">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Werner</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Egetemeyr</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Nadalin</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: Single center experience with telaprevir-based triple therapy</article-title>
          <source>Z Gastroenterol</source>
          <year>2014</year>
          <volume>52</volume>
          <fpage>27</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">24420796</pub-id>
        </element-citation>
      </ref>
      <ref id="b27-amjcaserep-17-605">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Clercq</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Current race in the development of DAAs (direct-acting antivirals) against HCV</article-title>
          <source>Biochem Pharmacol</source>
          <year>2014</year>
          <volume>89</volume>
          <fpage>441</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">24735613</pub-id>
        </element-citation>
      </ref>
      <ref id="b28-amjcaserep-17-605">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Afdhal</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zeuzem</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kwo</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <issue>20</issue>
          <fpage>1889</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">24725239</pub-id>
        </element-citation>
      </ref>
      <ref id="b29-amjcaserep-17-605">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Afdhal</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>DR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <issue>16</issue>
          <fpage>1483</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">24725238</pub-id>
        </element-citation>
      </ref>
      <ref id="b30-amjcaserep-17-605">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feld</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Kowdley</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Coakley</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of HCV with ABT-450/r, ombitasvir and dasabuvir with ribavirin</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <fpage>1594</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="pmid">24720703</pub-id>
        </element-citation>
      </ref>
      <ref id="b31-amjcaserep-17-605">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kowdley</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>KR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <issue>20</issue>
          <fpage>1879</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">24720702</pub-id>
        </element-citation>
      </ref>
      <ref id="b32-amjcaserep-17-605">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sulkowski</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Daclatasvir plus sofosbuvir for HCV infection</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <issue>16</issue>
          <fpage>1560</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">24738674</pub-id>
        </element-citation>
      </ref>
      <ref id="b33-amjcaserep-17-605">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwo</surname>
              <given-names>PY</given-names>
            </name>
          </person-group>
          <article-title>Direct acting antiviral therapy after liver transplantation</article-title>
          <source>Curr Opin Gastroenterol</source>
          <year>2016</year>
          <volume>32</volume>
          <issue>3</issue>
          <fpage>152</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="pmid">27023161</pub-id>
        </element-citation>
      </ref>
      <ref id="b34-amjcaserep-17-605">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charlton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gane</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Manns</surname>
              <given-names>MP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation</article-title>
          <source>Gastroenterology</source>
          <year>2015</year>
          <volume>148</volume>
          <issue>1</issue>
          <fpage>108</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="pmid">25304641</pub-id>
        </element-citation>
      </ref>
      <ref id="b35-amjcaserep-17-605">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curry</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Forns</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>RT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study</article-title>
          <source>Gastroenterology</source>
          <year>2015</year>
          <volume>148</volume>
          <issue>1</issue>
          <fpage>100</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">25261839</pub-id>
        </element-citation>
      </ref>
      <ref id="b36-amjcaserep-17-605">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woodfield</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Harness</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rix-Trott</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis C virus infections in oral and injectable drug users</article-title>
          <source>NZ Med J</source>
          <year>1993</year>
          <volume>106</volume>
          <fpage>332</fpage>
          <lpage>34</lpage>
        </element-citation>
      </ref>
      <ref id="b37-amjcaserep-17-605">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Vlahov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Correlates of hepatitis C virus infections among injection drug users</article-title>
          <source>Medicine (Balt)</source>
          <year>1995</year>
          <volume>74</volume>
          <fpage>212</fpage>
          <lpage>20</lpage>
        </element-citation>
      </ref>
      <ref id="b38-amjcaserep-17-605">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garfein</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Vlahov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Galai</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses</article-title>
          <source>Am J Public Health</source>
          <year>1996</year>
          <volume>86</volume>
          <fpage>655</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">8629715</pub-id>
        </element-citation>
      </ref>
      <ref id="b39-amjcaserep-17-605">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thiede</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hagan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murrill</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area</article-title>
          <source>J Urban Health: Bull NY Acad Med</source>
          <year>2000</year>
          <volume>77</volume>
          <fpage>331</fpage>
          <lpage>45</lpage>
        </element-citation>
      </ref>
      <ref id="b40-amjcaserep-17-605">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cook</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>McVeigh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Syed</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment</article-title>
          <source>Addiction</source>
          <year>2001</year>
          <volume>96</volume>
          <fpage>1787</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">11784471</pub-id>
        </element-citation>
      </ref>
      <ref id="b41-amjcaserep-17-605">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rhodes</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Platt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Maximova</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: A multi-city study</article-title>
          <source>Addiction</source>
          <year>2006</year>
          <volume>101</volume>
          <fpage>252</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">16445554</pub-id>
        </element-citation>
      </ref>
      <ref id="b42-amjcaserep-17-605">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faye-White</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garfein</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Brouwer</surname>
              <given-names>KC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S</article-title>
          <source>Salud Publica Mex</source>
          <year>2007</year>
          <volume>49</volume>
          <fpage>165</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">17589770</pub-id>
        </element-citation>
      </ref>
      <ref id="b43-amjcaserep-17-605">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peles</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rados</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Adelson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Characterization of former heroin addict patients with hepatitis C virus antibodies in a methadone maintenance treatment (MMT) clinic in Israel</article-title>
          <source>Subst Use Misuse</source>
          <year>2007</year>
          <volume>42</volume>
          <fpage>1477</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">17886143</pub-id>
        </element-citation>
      </ref>
      <ref id="b44-amjcaserep-17-605">
        <label>44.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kreek</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Rationale for maintenance pharmacotherapy of opiate dependence</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <source>Addictive States</source>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Raven Press</publisher-name>
          <year>1992</year>
          <fpage>205</fpage>
          <lpage>30</lpage>
        </element-citation>
      </ref>
      <ref id="b45-amjcaserep-17-605">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kreek</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>LaForge</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Butelman</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Pharmacotherapy of addictions</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2002</year>
          <volume>1</volume>
          <fpage>710</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">12209151</pub-id>
        </element-citation>
      </ref>
      <ref id="b46-amjcaserep-17-605">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanchana</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Kaul</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Manzarbeitia</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Liver transplantation for patients on methadone maintenance</article-title>
          <source>Liver Transpl</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>778</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">12200777</pub-id>
        </element-citation>
      </ref>
      <ref id="b47-amjcaserep-17-605">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>LU</given-names>
            </name>
            <name>
              <surname>Schiano</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation</article-title>
          <source>Am J Transpl</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>1273</fpage>
          <lpage>77</lpage>
        </element-citation>
      </ref>
      <ref id="b48-amjcaserep-17-605">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinrieb</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Barnett</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>KG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients</article-title>
          <source>Liver Transpl</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>97</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="pmid">14755785</pub-id>
        </element-citation>
      </ref>
      <ref id="b49-amjcaserep-17-605">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hancock</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Prosser</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Ransibrahmanakul</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Liver transplant and hepatitis C in methadone maintenance therapy: A case report</article-title>
          <source>Subst Abuse Treat Prevent Policy</source>
          <year>2007</year>
          <volume>2</volume>
          <fpage>5</fpage>
        </element-citation>
      </ref>
      <ref id="b50-amjcaserep-17-605">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robaeys</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nevens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>St&#xE4;rkel</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection</article-title>
          <source>Transplant Proc</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>589</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">19328933</pub-id>
        </element-citation>
      </ref>
      <ref id="b51-amjcaserep-17-605">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwo</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Badshah</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease</article-title>
          <source>Curr Opin Organ Transplant</source>
          <year>2015</year>
          <volume>20</volume>
          <fpage>235</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">25944238</pub-id>
        </element-citation>
      </ref>
      <ref id="b52-amjcaserep-17-605">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klaus</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Keitel da Silva</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Meinerz</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute kidney injury after liver transplantation: incidence and mortality</article-title>
          <source>Transplant Proc</source>
          <year>2014</year>
          <volume>6</volume>
          <fpage>1819</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">25131045</pub-id>
        </element-citation>
      </ref>
      <ref id="b53-amjcaserep-17-605">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fontana</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Bifano</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C</article-title>
          <source>Am J Transplant</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>1601</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">23593993</pub-id>
        </element-citation>
      </ref>
      <ref id="b54-amjcaserep-17-605">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poole</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Daclatasvir + asunaprevir: First global approval</article-title>
          <source>Drugs</source>
          <year>2014</year>
          <volume>74</volume>
          <fpage>1559</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">25117197</pub-id>
        </element-citation>
      </ref>
      <ref id="b55-amjcaserep-17-605">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Llad&#xF3;</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fabregat</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Castellote</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study</article-title>
          <source>Liver Transpl</source>
          <year>2008</year>
          <volume>14</volume>
          <issue>12</issue>
          <fpage>1752</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">19025919</pub-id>
        </element-citation>
      </ref>
      <ref id="b56-amjcaserep-17-605">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MacPhee</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Spreafico</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bewick</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure</article-title>
          <source>Kidney Int</source>
          <year>2000</year>
          <volume>57</volume>
          <issue>3</issue>
          <fpage>1164</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">10720968</pub-id>
        </element-citation>
      </ref>
      <ref id="b57-amjcaserep-17-605">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>H&#xFC;bner</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Eismann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sziegoleit</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolc acid monitoring in renal transplant patients</article-title>
          <source>Ther Drug Monit</source>
          <year>1999</year>
          <volume>21</volume>
          <issue>5</issue>
          <fpage>536</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="pmid">10519451</pub-id>
        </element-citation>
      </ref>
      <ref id="b58-amjcaserep-17-605">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Felipe</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Pinheiro-Machado</surname>
              <given-names>PG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tacrolimus pharacokinetic drug interactions: effect of predisone, mycophenolic acid or sirolimus</article-title>
          <source>Fundam Clin Pharmacol</source>
          <year>2009</year>
          <volume>23</volume>
          <issue>1</issue>
          <fpage>137</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">19267777</pub-id>
        </element-citation>
      </ref>
      <ref id="b59-amjcaserep-17-605">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>European Association for the Study of the Liver</collab>
          </person-group>
          <article-title>EASL recommendations on treatment of hepatitis C 2015</article-title>
          <source>J Hepatol</source>
          <year>2015</year>
          <volume>63</volume>
          <issue>1</issue>
          <fpage>199</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="pmid">25911336</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-amjcaserep-17-605" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>Time course of immunosuppressive regimen. This figure shows the time course of the patients TAC-level (black dots) and the according adaptions of the TAC dosage (in blue). Due to a massive drop of platelets observed on day 2 post-LT, MMF (in red) was paused for 14 days and the dosage reduced in the follow-up.</p>
        <p>TAC &#x2013; tacrolimus;</p>
        <p>MMF &#x2013; mycophenolate mofetil;</p>
        <p>LT &#x2013; liver transplantation.</p>
      </caption>
      <graphic xlink:href="amjcaserep-17-605-g001"/>
    </fig>
    <table-wrap id="t1-amjcaserep-17-605" position="float">
      <label>Table 1</label>
      <caption>
        <p>Course of laboratory parameters prior and after LT.</p>
      </caption>
      <table frame="hsides" rules="rows">
        <thead>
          <tr>
            <th valign="middle" align="center" rowspan="1" colspan="1"/>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>&#x2212;18 (days)</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>&#x2212;11</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>&#x2212;4</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>LT</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>+7</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>+16</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>+22</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>+30</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>+36</bold>
            </th>
            <th valign="middle" align="center" rowspan="1" colspan="1">
              <bold>+42</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">INR</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.88</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.87</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.68</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.76</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.30</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.03</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.18</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.16</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.13</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.13</td>
          </tr>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">BIL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>21.7</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>17.1</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>21.7</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>19.2</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>4.1</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.4</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.4</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.8</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.4</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.5</bold>
            </td>
          </tr>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">ALB</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.3</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.3</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.4</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.7</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.6</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.7</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>2.6</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>3.2</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>3.2</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">4.0</td>
          </tr>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">CREA</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.2</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.2</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.3</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.6</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.2</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&#x2013;</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&#x2013;</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>3.0</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1.3</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.1</td>
          </tr>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">AST</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>72</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>50</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>53</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>1074</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">22</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">16</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">18</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">24</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">25</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">30</td>
          </tr>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">ALT</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">44</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">32</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">33</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>412</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>45</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">19</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">17</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">21</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">14</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">18</td>
          </tr>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">gGT</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">50</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">48</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">43</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">32</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>722</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>392</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>123</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>193</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>111</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>93</bold>
            </td>
          </tr>
          <tr>
            <td valign="middle" align="center" rowspan="1" colspan="1">eGFR</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">49</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">
              <bold>23</bold>
            </td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&gt;60</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn1-amjcaserep-17-605">
          <p>This table shows the time course of all important laboratory parameters, starting from the beginning of the antiviral therapy. Parameters were collected prior to and after LT. The successful clinical course after LT under antiviral therapy as well as the transient renal injury (AKIN II) were noticeable. LT &#x2013; liver transplantation; INR &#x2013; international normalized ratio; BIL &#x2013; bilirubin; ALB &#x2013; albumin; CREA &#x2013; creatinine; GOT &#x2013; glutamic oxaloacetic transaminase; GPT &#x2013; glutamic-pyruvic transaminase; gGT &#x2013; gamma-glutamyl transferase; eGFR &#x2013; estimated glomerular filtration rate; bold values &#x2013; pathologic values.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
